After the FDA approved the use of JETREA injections to treat vitreomacular adhesion last October, Los Angeles-based Retina-Vitreous Associates Medical Group claims it is the first on the West Coast to use the drug to treat VMA patients non-surgically.
JETREA (ocriplasmin) is a proteolytic enzyme that is injected into the eye in a single dose to break down proteins that adhere the vitreous to the macula.
Ophthalmologist's Office Raided Amid Sex, Fraud Scandal
President Obama Presents Innovation Award to Lasik Inventor
JETREA (ocriplasmin) is a proteolytic enzyme that is injected into the eye in a single dose to break down proteins that adhere the vitreous to the macula.
More Articles on Ophthalmology:
Chesapeake Eye Care & Laser Center in Maryland Now Offers LenSx Cataract SurgeryOphthalmologist's Office Raided Amid Sex, Fraud Scandal
President Obama Presents Innovation Award to Lasik Inventor